The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK‐3 activities

• Published in: Journal of neurochemistry Vol. 126; no. 1; pp. 4 - 18
• Main Authors: Kao, Chien‐Yu, Hsu, Yi‐Chao, Liu, Jen‐Wei, Lee, Don‐Ching, Chung, Yu‐Fen, Chiu, Ing‐Ming
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.07.2013
• Subjects: Acetylation; Animals; Antimanic Agents - pharmacology; Bipolar disorder; Blotting, Western; Cell Differentiation - drug effects; Cell Line, Tumor; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; Embryonic Stem Cells - drug effects; FGF1; Fibroblast Growth Factor 1 - drug effects; Fibroblast Growth Factor 1 - genetics; Flow Cytometry; Gene expression; Glycogen Synthase Kinase 3 - antagonists & inhibitors; GSK‐3; HDACs; Histone Deacetylase Inhibitors; Histone Deacetylases - metabolism; Humans; Immunohistochemistry; Kinases; lithium; Lithium Chloride - pharmacology; Mice; Neural Stem Cells - drug effects; Neurochemistry; Polymerase Chain Reaction; Promoter Regions, Genetic - genetics; Psychopharmacology; RFX; RNA, Small Interfering - pharmacology; Transcriptional Activation - drug effects; Valproic Acid - pharmacology; VPA

Valproic acid (VPA) is the primary mood‐stabilizing drug to exert neuroprotective effects and to treat bipolar disorder in clinic. Fibroblast growth factor 1 (FGF1) has been shown to regulate cell proliferation, cell division, and neurogenesis. Human FGF1 gene 1B promoter (−540 to +31)‐driven green...